Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05036278 · ClinicalTrials.gov registry record · Phase 4
Prophylaxis Regimen for Hemophilia A Patients
A Phase 4 study of Hemophilia A and Prophylaxis of Bleeding, sponsored by Bayer.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
- 12
- Study locations
NCT05036278 is a Phase 4 study of Hemophilia A and Prophylaxis of Bleeding that has completed, run by Bayer. The registered enrollment target is 21 participants, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (77% lower). The trial reports 12 study locations across 9 states.
The verdict
NCT05036278, a Phase 4 study of Hemophilia A and Prophylaxis of Bleeding, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
- 12
- Study locations
Study Summary
Researchers are looking for a better way to treat people who have hemophilia A. Hemophilia A is a genetic bleeding disorder that is caused by the lack of a protein in the blood called "clotting factor 8" (FVIII). FVIII is naturally found in the blood where it causes the blood to clump together to help prevent and stop bleeding. People with lower levels of FVIII or with FVIII that does not work properly may bleed for a long time from minor wounds, have painful bleeding into joints, or have internal bleeding. The study treatment, Jivi (also called damoctocog alfa pegol), is already available for doctors to prescribe to people with hemophilia A to treat and prevent bleeding. It works by replacing the missing FVIII, or the FVIII that does not work properly. People with hemophilia A need frequent injections of FVIII products into the vein. So called standard half-life (SHL) products need to be given 2 to 4 times a week for the prevention of bleeding. In recent years, new products like Jivi called extended half-life (EHL) products have become available. These products last longer in the body so that they require to be given less often with injections every 3-5 days. Thus, these treatments may be easier and more comfortable to stick to in daily life. There is no general plan concerning the best amount of treatment and the frequency of injections for the prevention of bleeding, since the severity may be different and individual risk factors have to be considered. Doctors often decide on a treatment plan based on their experience. The main purpose of this study is to learn how well a new scoring approach works to select a treatment plan for the prevention of bleeding in people with hemophilia A who switch their treatment from SHL products to Jivi. Different types of information are used to calculate the risk score like bleeding history, certain biological factors, and physical activity of the participant. All participants will receive Jivi for 6 months. In the first fou
Conditions Studied
Interventions
- BIOLOGICAL Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).
Study Locations (12)
California
- Dr. Akshat Jain - Loma Linda University Medical Center - Loma Linda
- Loma Linda University Children's Hospital - Hematology / Oncology - Loma Linda
- Luskin Orthopaedic Institute for Children - Los Angeles
Georgia
- Aflac Cancer and Blood Disorders Center - Egleston Hospital - Atlanta
- Wellstar MCG Health Medical Center - Gynecology - Augusta
Colorado
- University of Colorado | Renal Research Office - Aurora
Florida
- UHealth - Sylvester Comprehensive Cancer Center - Miami
Illinois
- Rush University Medical Center - Oncology - Chicago
Iowa
- Stead Family Children's Hospital - Hematology / Oncology - Iowa City
Minnesota
- M Health Fairview Masonic Cancer Clinic - Clinics and Surgery Center - Minneapolis
New Jersey
- Rutgers Robert Wood Johnson Medical School - OBGYN - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-07-28 |
| Est. Completion | 2024-09-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05036278
The ClinicalTrials.gov registry entry for NCT05036278 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (77% lower). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG). is the first listed.
NCT05036278 reports 12 study locations spanning 9 distinct geographic areas - top geographies include California, Georgia, Colorado.
Frequently Asked Questions
What is clinical trial NCT05036278 about?
NCT05036278 is a clinical study titled "Prophylaxis Regimen for Hemophilia A Patients". Researchers are looking for a better way to treat people who have hemophilia A. Hemophilia A is a genetic bleeding disorder that is caused by the lack of a protein in the blood called "clotting factor 8" (FVIII). FVIII is naturally found in the blood where it causes the blood to clump together to he...
What is the current status of trial NCT05036278?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2022-07-28. Estimated completion is 2024-09-12.
What conditions does trial NCT05036278 study?
This clinical trial studies the following conditions: Hemophilia A, Prophylaxis of Bleeding.
What interventions are being tested in trial NCT05036278?
The interventions under investigation include: Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG). (BIOLOGICAL).
Who is sponsoring clinical trial NCT05036278?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05036278 being conducted?
This trial has 12 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
RECRUITING · Phase 4
-
A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
RECRUITING · Phase 4
-
POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
RECRUITING · Phase 4
-
Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies
COMPLETED · Phase 4
-
Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery
COMPLETED · Phase 4
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.